Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Little Green Pharma Ltd. ( (AU:LGP) ) has shared an announcement.
Little Green Pharma has confirmed the dispatch of the scheme booklet to shareholders of Cannatrek Ltd. as part of its proposed acquisition of 100% of Cannatrek via a scheme of arrangement. The booklet, available electronically and in hard copy, outlines details of the deal, voting procedures, and LGP’s intentions for Cannatrek following implementation.
An independent expert from RSM Corporate Australia has concluded that the scheme is fair and reasonable and in the best interests of Cannatrek shareholders, absent a superior proposal. Both the Cannatrek and LGP boards have unanimously recommended that their respective shareholders vote in favour of the transaction, underscoring strong board-level support for the combination and its expected strategic benefits.
The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.
More about Little Green Pharma Ltd.
Little Green Pharma Ltd. is an Australia-based medicinal cannabis company focused on the cultivation, manufacture, and supply of cannabis-based medicines. The company targets the regulated medical market and is listed on the ASX under the ticker LGP, seeking growth through strategic acquisitions in the cannabis sector.
Average Trading Volume: 208,144
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$33.64M
See more data about LGP stock on TipRanks’ Stock Analysis page.